Overview

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI) Active Control.
Phase:
Phase 2
Details
Lead Sponsor:
Amphastar Pharmaceuticals, Inc.
Treatments:
Albuterol